Markets:

Overview

News

Currencies

International

Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

12.75 -0.47 (-3.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

MiNK Therapeutics (INKT) Earnings Call Transcript ↗

November 14, 2025

MiNK Therapeutics (INKT) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

November 14, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics's Earnings Outlook ↗

November 13, 2025

Via Benzinga

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

November 07, 2025

From MiNK Therapeutics

Via GlobeNewswire

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Earnings Scheduled For November 14, 2025 ↗

November 14, 2025

Via Benzinga

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

November 05, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

October 30, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

September 29, 2025

Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

September 25, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

September 18, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics Extends Cash Runway ↗

August 14, 2025

Via The Motley Fool

MiNK INKT Q2 2025 Earnings Call Transcript ↗

August 14, 2025

Via The Motley Fool

Topics Earnings

MiNK Therapeutics Inc (NASDAQ:INKT) Reports Wider Q2 2025 Loss, Advances Clinical Pipeline Amid Market Caution ↗

August 14, 2025

MiNK Therapeutics Q2 2025 earnings miss EPS estimates with a $1.06 loss per share, but cash runway extends to mid-2026. Clinical progress in cancer and GvHD offers future potential.

Via Chartmill

Topics Earnings

MiNK Therapeutics Cuts Q2 Cash Use 31% ↗

August 14, 2025

Via The Motley Fool

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

August 14, 2025

From MiNK Therapeutics

Via GlobeNewswire

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

July 31, 2025

From MiNK Therapeutics

Via GlobeNewswire

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

July 17, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 15, 2025

Via Benzinga

Which stocks are moving on Tuesday? ↗

July 15, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

July 15, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

July 15, 2025

iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy

From MiNK Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

July 15, 2025

Via Benzinga

These stocks are moving in today's session ↗

July 14, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 14, 2025

Via Benzinga

Unusual volume stocks in Monday's session ↗

July 14, 2025

Unusual volume stocks in Monday's session

Via Chartmill

Which stocks are moving on Monday? ↗

July 14, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 14, 2025

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

All News about MiNK Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today